120 related articles for article (PubMed ID: 7999402)
1. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study.
Murray PA; Gomm J; Ricketts D; Powles T; Coombes RC
Eur J Cancer; 1994; 30A(9):1218-22. PubMed ID: 7999402
[TBL] [Abstract][Full Text] [Related]
2. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
3. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
[TBL] [Abstract][Full Text] [Related]
4. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
Rexhepaj E; Brennan DJ; Holloway P; Kay EW; McCann AH; Landberg G; Duffy MJ; Jirstrom K; Gallagher WM
Breast Cancer Res; 2008; 10(5):R89. PubMed ID: 18947395
[TBL] [Abstract][Full Text] [Related]
5. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
Seymour L; Bezwoda WR
Br J Cancer; 1993 Aug; 68(2):352-6. PubMed ID: 8347490
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor.
Luqmani YA; Ricketts D; Ryall G; Turnbull L; Law M; Coombes RC
Int J Cancer; 1993 Jun; 54(4):619-23. PubMed ID: 8514453
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
8. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer.
Noguchi S; Motomura K; Inaji H; Imaoka S; Koyama H
Cancer; 1993 Jul; 72(1):131-6. PubMed ID: 8508397
[TBL] [Abstract][Full Text] [Related]
11. [Expression of oestrogen receptor-beta in invasive breast tumours].
Péter I; Számel I; Péley G
Magy Onkol; 2004; 48(1):63-9. PubMed ID: 15105898
[TBL] [Abstract][Full Text] [Related]
12. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
13. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
14. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.
Kopp A; Jonat W; Schmahl M; Knabbe C
Cancer Res; 1995 Oct; 55(20):4512-5. PubMed ID: 7553618
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.
Barnes DM; Harris WH; Smith P; Millis RR; Rubens RD
Br J Cancer; 1996 Nov; 74(9):1445-51. PubMed ID: 8912543
[TBL] [Abstract][Full Text] [Related]
18. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
19. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
[TBL] [Abstract][Full Text] [Related]
20. Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D.
Dannecker C; Possinger K; Classen S
Ann Oncol; 1996 Apr; 7(4):391-5. PubMed ID: 8805931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
